Century Therapeutics, Inc. cash flow to debt ratio of -238.44% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Century Therapeutics, Inc.'s free cash flow has increased -5.05% from $-110.29M last year to $-104.72M, signaling increasing performance

Century Therapeutics, Inc.'s debt to equity ratio is 0.18, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Century Therapeutics, Inc.'s debt has decreased relative to shareholder equity from 0.33 last year to 0.18 today, signaling strengthened financials

Century Therapeutics, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

Century Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Century Therapeutics, Inc.'s profit margin has increased (-100.00%) in the last year from -1.92K% to 0.00%, signaling increasing performance

Century Therapeutics, Inc.'s short-term assets of $120.77M exceed its short-term liabilities of $20.23M

Century Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Century Therapeutics, Inc.'s return on equity of -53.23%, is lower than 15.00%, indicating bad performance

Century Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Century Therapeutics, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Century Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Century Therapeutics, Inc. has negative free cash flow, indicating cash burn

Century Therapeutics, Inc.'s yearly earnings has increased -92.43% since last year from $-126.57M to $-9.58M, signaling increasing performance

Century Therapeutics, Inc.'s yearly revenue has increased 1.56K% since last year from $6.59M to $109.16M, signaling increasing performance

ROIC -36.86% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Century Therapeutics, Inc.'s 3-year revenue CAGR of 175.88% is positive, indicating growing revenue over the past 3 years

Century Therapeutics, Inc. had revenue growth in 4.00 out of 5 years, indicating consistent revenue performance

Century Therapeutics, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Century Therapeutics, Inc. has insufficient data to evaluate this check.

Century Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Century Therapeutics, Inc. is overvalued relative to its fair value price of 0.06 based on EBITDA multiple model

Century Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Century Therapeutics, Inc. has insufficient data to evaluate this check.

Century Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Century Therapeutics, Inc. has a price-to-book ratio of 0.76x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Century Therapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue